Page 62 - Read Online

Zhang et al. Neuroimmunol Neuroinflammation 2019;6:8 I http://dx.doi.org/10.20517/2347-8659.2019.06 Page 11 of 16

13. Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, et al. Multiple sclerosis: immunopathology and treatment update.
Brain Sci 2017;7:E78.
14. Lovett-Racke AE, Yang Y, Racke MK. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta
2011;1812:246-51.
15. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015;5:e00362.
16. Lehmann PV, Rottlaender A, Kuerten S. The autoimmune pathogenesis of multiple sclerosis. Pharmazie 2015;70:5-11.
17. Van Kaer L, Wu L, Parekh VV. Natural killer t cells in multiple sclerosis and its animal model, experimental autoimmune
encephalomyelitis. Immunology 2015;146:1-10.
18. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545-58.
19. von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS, et al. Update on the autoimmune pathology of multiple
sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol 2015;73:238-46.
20. Bennett JL, O’Connor KC, Bar-Or A, Zamvil SS, Hemmer B, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol
Neuroinflamm 2015;2:e104.
21. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 2008;5:22.
22. Hertwig L, Pache F, Romero-Suarez S, Stürner KH, Borisow N, et al. Distinct functionality of neutrophils in multiple sclerosis and
neuromyelitis optica. Mult Scler 2016;22:160-73.
23. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F, et al. Diagnosis and treatment of NMO spectrum disorder and MOG-
encephalomyelitis. Front Neurol 2018;9:888.
24. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, et al. MOG antibody disease: a review of MOG antibody seropositive
neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018;25:66-72.
25. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO
spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015;2:e62.
26. Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ, et al. Neuromyelitis optica spectrum disorders: comparison of clinica
land magnetic resonanceimaging characteristics of AQP4-IgG versus MOG- IgG seropositive cases in the Netherlands. EurJNeurol
2016;23:580-7.
27. Vourc’h P, Andres C. Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function. Brain Res Brain Res Rev
2004;45:115-24.
28. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients.
Part 1: frequency, syndrome specificity, influence of disease activity, longterm course, association with AQP4-IgG, and origin. J
Neuroinflamm 2016;13:279.
29. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive
neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306:82-90.
30. Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, et al. Aquaporin-4 serostatus does not predict response to
immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler 2018;24:1737-42.
31. Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, et al. MOG-IgG in primary and secondary chronic progressive multiple
sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflamm 2018;15:88.
32. Diebold M, Derfuss T. Immunological treatment of multiple sclerosis. Semin Hematol 2016;53:S54-7.
33. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 2016;13:70-83.
34. Inglese M, Petracca M. Therapeutic strategies in multiple sclerosis: a focus on neuroprotection and repair and relevance to
schizophrenia. Schizophr Res 2015;161:94-101.
35. Morrow SA, Metz LM, Kremenchutzky M. High dose oral steroids commonly used to treat relapses in canadian ms clinics. Can J
Neurol Sci 2009;36:213-5.
36. Compston DA, Milligan NM, Hughes PJ, Gibbs J, McBroom V, et al. A double-blind controlled trial of high dose methylprednisolone in
patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry 1987;50:517-22.
37. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous
methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-22.
38. Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012;2012:787630.
39. Trebst C, Bronzlik P, Kielstein JT, Schmidt BM, Stangel M, et al. Immunoadsorption therapy for steroid-unresponsive relapses in
patients with multiple sclerosis. Blood Purif 2012;33:1-6.
40. Koziolek MJ, Tampe D, Bahr M, Dihazi H, Jung K, et al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-
refractory optical neuritis. J Neuroinflammation 2012;9:80.
41. Trebst C, Jarius S, Berthele A, Paul F, Schippling S. et al. Update on the diagnosis and treatment of neuromyelitis optica:
recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1-16.
42. Elovaara I, Kuusisto H, Wu X, Rinta S, Dastidar P, et al. Intravenous immunoglobulins are a therapeutic option in the treatment of
multiple sclerosis relapse. Clin Neuropharmacol. 2011;34:84-9.
43. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of
neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20:501-4.
44. William M, Carroll, Kazuo Fujihara. Neuromyelitis optica. Neurology 2010;12:244-55.
45. Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 2013;33:S33-7.
46. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med
1999;340:227-8.
47. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005;11:425-
32.